QbD-driven development of phospholipid-embedded lipidic nanocarriers of raloxifene: extensive in vitro and in vivo evaluation studies

Raloxifene (RLX) is popularly indicated in treatment of osteoporosis and prevention of breast cancer. Owing to its poor aqueous solubility, high pre-systemic metabolism, intestinal glucuronidation, and P-glycoprotein (P-gp) efflux, however, it demonstrates low (

Saved in:
Bibliographic Details
Published in:Drug delivery and translational research 2024-03, Vol.14 (3), p.730-756
Main Authors: Pant, Anjali, Sharma, Gajanand, Saini, Sumant, Kaur, Gurjeet, Jain, Atul, Thakur, Anil, Singh, Bhupinder
Format: Article
Language:English
Subjects:
Biomedical and Life Sciences
Biomedicine
Original Article
Pharmaceutical Sciences/Technology
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Raloxifene (RLX) is popularly indicated in treatment of osteoporosis and prevention of breast cancer. Owing to its poor aqueous solubility, high pre-systemic metabolism, intestinal glucuronidation, and P-glycoprotein (P-gp) efflux, however, it demonstrates low (
ISSN:2190-393X
2190-3948
DOI:10.1007/s13346-023-01427-3